Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Impax Labs. Introduces Oxymorphone Hydrochloride Extended-Release Tablets

RELATED NEWS
Trade IPXL now with 

Impax Laboratories Inc.(IPXL: Quote) said it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, via. Global Pharmaceuticals, Impax's generics unit.

In June 2010, Impax inked a deal with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle U.S. patent litigation concerning the production and sale of its Oxymorphone Hydrochloride Extended-Release Tablets approved by the U.S. Food and Drug Administration as therapeutically equivalent to the original formulation of OPANA ER. According to the settlement, Endo agreed to grant Impax a license to sell Impax's approved product on January 1, 2013.

Impax also noted that it is actively participating in efforts to support prescriber and patient education of this product through the FDA-approved Risk Evaluation and Mitigation Strategy. Oxymorphone Hydrochloride Extended-Release Tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

Click here to receive FREE breaking news email alerts for Impax Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.